A meta-analysis of 346 phase I clinical trials, involving more than 13,000 patients, found that selecting treatment based on a tumor’s molecular characteristics led to significantly better outcomes.
Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.
